| Prev Close | 7.34 |
| Open | 7.24 |
| Day Low/High | 7.10 / 7.40 |
| 52 Wk Low/High | 6.04 / 24.37 |
| Volume | 3.01M |
| Avg Volume | 9.00M |
Cronos Group Inc. (CRON)
7.18
0.16
2.20
NASDAQ : Process Industries
| Exchange | NASDAQ |
| Shares Outstanding | 343.76M |
| Market Cap | 2.51B |
| EPS | -0.10 |
| P/E Ratio | 8.44 |
| Div & Yield | N.A. (N.A) |
Latest News
Cannabis High
Cannabis stocks are continuing to get their groove back this morning - with good gains in , , , and .
Let's Get Chai!
Here is your Marijuana Moment. Last week, my Trade of the Week (and a half!) was a basket of cannabis stocks -- and I moved to large sized in all of them during the week (Note: The stocks started to roll higher on Friday): My package includes ($7.0...
Trade of the Week - A Package of Speculative Cannabis Stocks
* My package includes ($7.00), ($5.69), ($5.45), ($2.25) and ($8.15) * It is likely that the maximum tax selling pressure is now virtually over * While technically "The Trade of the Week" - this is my favorite group to benefit from the "January Effe...
Adding to Cannabis
* In the hope for a "January Effect" after tax loss selling in December I added to ($7.82), ($6.70), ($5.90), ($5.29) and ($2.19) today.
Cannabis a Rising Star in Morningstar Mag
Morningstar Magazine offers insight into future growth potential for cannabis industry and stocks.
Don't Fight the Trend on These 3 Cannabis Stocks
A look at what the weekly charts of three big cannabis names are saying.
New Buy (and Short) Levels
* My revised levels I don't want there to be any ambiguity about the size of my positions or about my buy and short levels as I strive for as much transparency as possible. "When the time comes to buy, you won't want to." - Walter Deemer "When the t...
Cannabis Moves
I am adding names to my basket of cannabis stocks - including ($8.80), and a number of very small speculative stocks that are too racy to name.
Cronos Group Is Still Coming Down From Its High
Shares of the cannabis company are likely to drift lower in the weeks ahead.
Cronos Group Could Break Key Moving Averages - Protect Long Positions
Let's look at the chart of CRON.
Morningstar High on Pot Growth, Sees U.S. Going Legal by 2023
Analysts say nation will turn a new leaf, changing federal law within a few years, as cannabis industry expected to grow big time over next decade.
Would You Rather Have an Executive Team Managing the Company or the Stock Price?
It all comes down to matching my time frame.
OrganiGram Could Climb Higher, but You Need Discipline Before Buying
Here's how to play OGI stock right now.
5 Cannabis ETFs to Fire Up Your Portfolio
Two of them are brand new.
Prohibition and the Paradoxical Proclivity of Cannabis Consumption
Is prohibition the real factor propping up projections for demand and pricing in the cannabis market?
Should Investors Buy the Dip in Canopy Growth Stock?
Canopy's earnings losses could just be a stepping stone to becoming the industry leader.
Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space
CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
Cronos Group's High Times May Be About to Wear Off
Charts of this type are frequently found to be topping patterns.
Altria or Philip Morris International: Which Is the Better Dividend Stock?
While the two tobacco giants have similar yields, both also have very different businesses, with different growth potential in the years ahead.
Use Caution on Small-Caps, Plus Apple, Tesla and McDonald's: Market Recon
Equity markets marked time on Monday, mostly on light volume.
Cronos Group Certainly Qualifies for Mainstream Consideration
Revenue is where it's at for cannabis in 2019.
2 Big Earnings Reports I'll Be Watching This Week
A huge week is coming up for these well-known stocks.
7 Indirect Stock Plays on the Cannabis Sector
Investors can gain exposure to the high-flying cannabis industry without taking on undue risks.
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
